Applied Biosystems, a division of Life Technologies Corporation, has announced that scientists at bioMerieux and the Institute of Analytical Sciences at the University of Lyon in France are collaborating on research to advance the discovery of biomarkers that can be used to diagnose or monitor disease. They are using next-generation, mass spectrometry technology with integrated triple quadrupoles and a linear accelerator trap to validate newly identified candidate biomarkers.
To accomplish these goals, they are using AB SCIEX QTRAP 5500 Systems that quantify dozens of protein and peptide biomarkers in a single analysis. The AB SCIEX QTRAP 5500 System, which was developed by the Applied Biosystems/MDS Analytical Technologies joint venture, offers greater reproducibility and precision than other mass spectrometry platforms and provides faster and more specific results than the current clinical standard of antibody-based testing, making this new technology ideal for protein biomarker validation. These AB SCIEX QTRAP 5500 Systems are being used to develop simple assays for detecting biomarkers that could then be transferred into standard testing procedures in diagnostic laboratories.
Biomarkers are indicators of the presence or progression of a disease that offer a quick and easy method for diagnosing or monitoring patients for a range of conditions, including cancers as well as infectious and degenerative diseases.
Extensive research is required to clarify the exact role and significance of each newly discovered candidate biomarker, which is a process that can take several years to complete. The scientists from bioMérieux and the University of Lyon are combining their respective expertise in biomarker discovery and protein mass spectrometry to accelerate this biomarker validation process.
Jean-Philippe Charrier, Immunoproteomics Senior Staff Scientist at bioMerieux, “bioMerieux is boosting its capabilities for targeted, fast, and efficient biomarker research and validation. The AB SCIEX QTRAP 5500 System gives us testing capabilities above and beyond what currently exists and we expect them to help us advance our projects.”
Laura Lauman, President of Life Technologies’ Mass Spectrometry Systems Division, “This project is helping researchers make significant advances in biomarker research more rapidly than was previously possible. This demonstrates how our next generation of mass spectrometry systems is setting new standards of performance that respond to the dynamic needs of scientists looking to advance their understanding of diseases.”